Equities Analysts Set Expectations for MAZE FY2030 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Maze Therapeutics in a report issued on Monday, January 26th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings of $0.60 per share for the year. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock.

A number of other research analysts have also weighed in on MAZE. Guggenheim reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Friday, December 19th. Raymond James Financial initiated coverage on Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective on the stock. BTIG Research upped their target price on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a report on Friday, January 16th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, Wedbush raised their price objective on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Trading Up 1.7%

NASDAQ:MAZE opened at $45.34 on Wednesday. The company has a market cap of $2.18 billion and a P/E ratio of -2.17. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $47.36. The company’s 50-day moving average price is $40.36 and its 200-day moving average price is $28.57.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. boosted its holdings in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the period. Vanguard Group Inc. increased its stake in Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Woodline Partners LP lifted its position in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period. Finally, ArrowMark Colorado Holdings LLC acquired a new position in shares of Maze Therapeutics in the third quarter valued at approximately $14,135,000.

Insider Activity

In other news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares in the company, valued at approximately $426,001.68. This represents a 87.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $45.52, for a total transaction of $227,600.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $590,166.80. This trade represents a 27.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 172,500 shares of company stock valued at $7,002,267.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.